Wolfgang Miesbach: What Does Acquired Haemophilia A Truly cost, Clinically and Economically?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Real-world data from Munich – what does acquired haemophilia A truly cost, clinically and economically?
Great data presented at GTH2026 in Bonn by Seidl, Weiglein, Möhnle et al. from University Hospital LMU Munich – a retrospective single-center analysis of 51 adult AHA patients diagnosed between 2011 and 2023.
Patient characteristics:
- Median age 76 years – elderly, multimorbid
- Median FVIII activity 4% Median inhibitor titer 19 BU Median aPTT 72 sec
- Median hospital stay 38 days | Median ICU stay 10.5 days
- Etiology: 59% idiopathic, 27% autoimmune, 8% malignancy-associated, 6% postpartum
Clinical outcomes:
- 100-day mortality nearly 12%, 1-year mortality nearly 19%
- Early deaths primarily bleeding- and infection-related
- Severe bleeding (EACH2) independently associated with reduced overall survival (p is equal to 0.002)
- Low baseline FVIII activity independently predicted worse outcomes
Treatment reality:
43% steroids alone – but 57% needed combination immunosuppression
Emicizumab used for bleeding prophylaxis in 5 patients (9.8%)
The cost dimension for the period 2011-2023:
Median in-hospital drug costs: €130,069 per patient
More than 95% driven by bypassing agents and factor replacement”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series